Tam, Hoi Ki Joshua http://orcid.org/0000-0003-0293-3165
Robinson, Philip C. http://orcid.org/0000-0002-3156-3418
Nash, Peter http://orcid.org/0000-0002-2571-788X
Funding for this research was provided by:
The University of Queensland
Article History
Accepted: 29 June 2022
First Online: 21 July 2022
Declarations
:
: HJKT has no disclosures. PR reports personal fees from AbbVie, Atom Biosciences, Eli Lilly, Gilead, GlaxoSmithKline, Janssen, Kukdong, Novartis, UCB, Roche, and Pfizer; meeting attendance support from BMS, Pfizer, and UCB; and grant funding from Janssen, Novartis, Pfizer, and UCB Pharma. PN reports grants for research and clinical trials and honoraria for advice and lectures on behalf of AbbVie, BMS, Celgene, Pfizer, Roche, Samsung, Boehringer Ingelheim, Lilly, Novartis, Janssen, UCB, Gilead/Galapagos, GSK, MSD, and Sanofi.
: This article does not contain any studies with human or animal subjects performed by any of the authors.